Savior Lifetec Corporation (4167.TWO)
- Previous Close
19.95 - Open
20.80 - Bid 20.40 x --
- Ask 20.45 x --
- Day's Range
20.20 - 21.00 - 52 Week Range
14.35 - 27.80 - Volume
1,433,216 - Avg. Volume
897,751 - Market Cap (intraday)
6.491B - Beta (5Y Monthly) 0.53
- PE Ratio (TTM)
35.88 - EPS (TTM)
0.57 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield 0.09 (0.43%)
- Ex-Dividend Date Jul 12, 2024
- 1y Target Est
--
Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, meropenem, and ertapenem products. The company was founded in 1993 and is headquartered in Miaoli County, Taiwan.
www.saviorlifetec.com.tw/en/Recent News: 4167.TWO
View MorePerformance Overview: 4167.TWO
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4167.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4167.TWO
View MoreValuation Measures
Market Cap
6.33B
Enterprise Value
4.39B
Trailing P/E
35.00
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.24
Price/Book (mrq)
1.80
Enterprise Value/Revenue
3.61
Enterprise Value/EBITDA
13.99
Financial Highlights
Profitability and Income Statement
Profit Margin
14.98%
Return on Assets (ttm)
1.81%
Return on Equity (ttm)
5.19%
Revenue (ttm)
1.22B
Net Income Avi to Common (ttm)
182.38M
Diluted EPS (ttm)
0.57
Balance Sheet and Cash Flow
Total Cash (mrq)
2.12B
Total Debt/Equity (mrq)
5.06%
Levered Free Cash Flow (ttm)
651.74M